An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19

NCT04412018 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

100

Enrollment

OTHER

Sponsor class

Conditions

COVID-19
Inflammatory Response

Interventions

DRUG: Icosapent ethyl

Sponsor

Canadian Medical and Surgical Knowledge Translation Research Group

Collaborators

[object Object]
[object Object]